Reuters logo
BRIEF-Medivir: Janssen discontinues development of JNJ-4178 for hepatitis C
September 11, 2017 / 7:01 AM / 3 months ago

BRIEF-Medivir: Janssen discontinues development of JNJ-4178 for hepatitis C

Sept 11 (Reuters) - Medivir

* Medivir announces Janssen to discontinue development of JNJ-4178 for hepatitis C

* Says ongoing phase ii studies with JNJ-4178 will continue as planned, but there will be no additional development thereafter.

* Says discontinuation of development of JNJ-4178 does not affect ongoing partnership with Janssen on Olysio (simeprevir), or existing licensing agreement with Janssen in which simeprevir is included Source text for Eikon: Further company coverage: (Stockholm Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below